Evidence map›Paper›PMID 38899375›Full record

ReviewMolecular oncology2024

From bedside to bench: New insights in epilepsy-associated tumors based on recent classification updates and animal models on brain tumor networks.

Silvia Cases-Cunillera, Lea L Friker, Philipp Müller, Albert J Becker, Gerrit H Gielen

Abstract readReview
In one paragraph

Review in Molecular oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Silvia Cases-CunilleraINSERM U1266, Neuronal Signaling in Epilepsy and Glioma, Institute of Psychiatry and Neuroscience of Paris (IPNP), Université Paris Cité, Paris, France.
Lea L FrikerInstitute of Neuropathology, University Hospital Bonn, Bonn, Germany.
Philipp MüllerSection for Translational Epilepsy Research, Institute of Neuropathology, University Hospital Bonn, Bonn, Germany.
Albert J BeckerSection for Translational Epilepsy Research, Institute of Neuropathology, University Hospital Bonn, Bonn, Germany.
Gerrit H GielenInstitute of Neuropathology, University Hospital Bonn, Bonn, Germany.ORCID 0000-0002-2707-0290

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low-grade neuroepithelial tumors (LGNTs), particularly those with glioneuronal histology, are highly associated with pharmacoresistant epilepsy. Increasing research focused on these neoplastic lesions did not translate into drug discovery; and anticonvulsant or antitumor therapies are not available yet. During the last years, animal modeling has improved, thereby leading to the possibility of generating brain tumors in mice mimicking crucial genetic, molecular and immunohistological features. Among them, intraventricular in utero electroporation (IUE) has been proven to be a valuable tool for the generation of animal models for LGNTs allowing endogenous tumor growth within the mouse brain parenchyma. Epileptogenicity is mostly determined by the slow-growing patterns of these tumors, thus mirroring intrinsic interactions between tumor cells and surrounding neurons is crucial to investigate the mechanisms underlying convulsive activity. In this review, we provide an updated classification of the human LGNT and summarize the most recent data from human and animal models, with a focus on the crosstalk between brain tumors and neuronal function.

Indexed as

Brain NeoplasmsDisease Models, AnimalEpilepsyAnimalsHumansMiceNeoplasms, NeuroepithelialTranslational Research, Biomedicalbrain tumorsepilepsyin utero electroporationmouse modelneuronal activity

Identifiers

PMID38899375
PMCPMC11619802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.